Biogen Secures FDA Nod for Higher Dose of SMA Drug Spinraza

Key Takeaways Biogen shares rose after the FDA approved a higher-dose Spinraza regimen for SMA treatment.New dosing reduces frequency and shows improved motor function in DEVOTE study patients.Approval may help Biogen counter competition that has pressured Spinraza sales recently.Shares of Biogen (BIIB) rose 2% on Monday after the company announced that the FDA approved a higher dose of its blockbuster spinal muscular atrophy (SMA) drug Spinraza.The new dosing regimen simplifies administration by offering t ...